SG11202110742TA - Compounds targeting prmt5 - Google Patents

Compounds targeting prmt5

Info

Publication number
SG11202110742TA
SG11202110742TA SG11202110742TA SG11202110742TA SG11202110742TA SG 11202110742T A SG11202110742T A SG 11202110742TA SG 11202110742T A SG11202110742T A SG 11202110742TA SG 11202110742T A SG11202110742T A SG 11202110742TA SG 11202110742T A SG11202110742T A SG 11202110742TA
Authority
SG
Singapore
Prior art keywords
compounds targeting
prmt5
targeting prmt5
compounds
targeting
Prior art date
Application number
SG11202110742TA
Inventor
Koen Vandyck
Pierre Jean-Marie Bernard Raboisson
Jerome Deval
Leonid Beigelman
David Mcgowan
Yannick Debing
Original Assignee
Aligos Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aligos Therapeutics Inc filed Critical Aligos Therapeutics Inc
Publication of SG11202110742TA publication Critical patent/SG11202110742TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
SG11202110742TA 2019-04-02 2020-03-31 Compounds targeting prmt5 SG11202110742TA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962828282P 2019-04-02 2019-04-02
US201962877411P 2019-07-23 2019-07-23
US201962946649P 2019-12-11 2019-12-11
PCT/US2020/025966 WO2020205867A1 (en) 2019-04-02 2020-03-31 Compounds targeting prmt5

Publications (1)

Publication Number Publication Date
SG11202110742TA true SG11202110742TA (en) 2021-10-28

Family

ID=72661994

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202110742TA SG11202110742TA (en) 2019-04-02 2020-03-31 Compounds targeting prmt5

Country Status (14)

Country Link
US (2) US11198699B2 (en)
EP (1) EP3947388A4 (en)
JP (1) JP2022522534A (en)
KR (1) KR20210145787A (en)
CN (1) CN114072407A (en)
AU (1) AU2020256166A1 (en)
BR (1) BR112021019465A8 (en)
CA (1) CA3134613A1 (en)
IL (1) IL286849A (en)
MA (1) MA55556A (en)
MX (1) MX2021011606A (en)
SG (1) SG11202110742TA (en)
TW (1) TW202102509A (en)
WO (1) WO2020205867A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11077101B1 (en) 2018-07-18 2021-08-03 Tango Therapeutics, Inc. Compounds and methods of use
US20210277009A1 (en) * 2018-08-07 2021-09-09 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2020033284A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
BR112021019465A8 (en) * 2019-04-02 2022-06-07 Aligos Therapeutics Inc Compounds that target prmt5
CA3163421A1 (en) 2019-12-03 2021-06-10 Lupin Limited Substituted nucleoside analogs as prmt5 inhibitors
US20220112194A1 (en) * 2020-04-01 2022-04-14 Aligos Therapeutics, Inc. Compounds targeting prmt5
IL300147A (en) 2020-07-31 2023-03-01 Tango Therapeutics Inc Piperidin-1-yl-n-pyryidine-3-yl-2- oxoacetamide derivatives useful for the treatment of mtap-deficient and/or mta-accumulating cancers
CN117157297A (en) * 2021-07-20 2023-12-01 上海齐鲁制药研究中心有限公司 PRMT5 inhibitors
CN116655638B (en) * 2022-05-12 2024-01-26 上海齐鲁制药研究中心有限公司 Deuterated PRMT5 inhibitors

Family Cites Families (191)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR927003044A (en) 1990-01-11 1992-12-17 크리스토퍼 케이. 미라벨리 Composition and method for detecting and regulating RNA activity and gene expression
DE69120699T2 (en) 1990-03-08 1997-01-09 Fujisawa Pharmaceutical Co N-Monosubstituted cyclopentenylamines, a process for their preparation, and their use as a medicament
CA2133325A1 (en) 1992-04-21 1993-10-28 I. Charles Pathirana Non-steroid progesterone receptor agonist and antagonist compounds and methods
GB9307694D0 (en) 1993-04-14 1993-06-02 Smithkine Beecham Corp Novel compounds
GB2291872A (en) 1994-08-02 1996-02-07 Zeneca Ltd Alkyl cyclopentane-carboxylate fungicides
US5681940A (en) 1994-11-02 1997-10-28 Icn Pharmaceuticals Sugar modified nucleosides and oligonucleotides
SK57097A3 (en) 1994-11-07 1998-10-07 Pfizer Certain substituted benzylamine derivatives; a new class of neuropeptide y1 specific ligands
US5900415A (en) 1994-11-07 1999-05-04 Pfizer Inc. Certain substituted benzylamine derivatives; a new class of neuropeptide Y1 specific ligands
DE19501482A1 (en) 1995-01-19 1996-07-25 Bayer Ag 2,9-disubstituted purine-6-ones
US5514505A (en) 1995-05-15 1996-05-07 Xerox Corporation Method for obtaining improved image contrast in migration imaging members
WO1998003492A1 (en) 1996-07-23 1998-01-29 Neurogen Corporation Certain substituted benzylamine derivatives; a new class of neuropeptide y1 specific ligands
EP0918761B1 (en) 1996-07-23 2003-05-02 Neurogen Corporation Certain amido- and amino-substituted benzylamine derivatives; a new class of neuropeptite y1 specific ligands
JP2000515151A (en) 1996-07-23 2000-11-14 ニューロジェン・コーポレーション Specific substituted benzylamine derivatives; a new class of neuropeptides-Y1-specific ligands
SI20024A (en) 1996-10-16 2000-02-29 Icn Pharmaceuticals, Inc. Purine l-nucleosides, analogs and uses thereof
WO1999032486A1 (en) 1997-12-23 1999-07-01 Alcon Laboratories, Inc. Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions
AU2095099A (en) 1997-12-23 1999-07-12 Alcon Laboratories, Inc. Phthalimide-piperidine, -pyrrolidine and -azepine derivatives, their preparationand their use as muscarinic receptor (ant-)agonists
WO1999032489A1 (en) 1997-12-23 1999-07-01 Alcon Laboratories, Inc. Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions
AU2307999A (en) 1997-12-23 1999-07-12 Alcon Laboratories, Inc. Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions
WO1999032445A1 (en) 1997-12-23 1999-07-01 Alcon Laboratories, Inc. Oximino-piperidine, -pyrrolidine and -azepine derivatives, their preparation and their use as muscarinic receptor (ant-)agonists
WO1999032443A1 (en) 1997-12-23 1999-07-01 Alcon Laboratories, Inc. Muscarinic agents and use thereof to treat glaucoma, myopia, and various other conditions
EP1087938A1 (en) 1998-04-23 2001-04-04 Abbott Laboratories Inhibitors of neuraminidases
US6518305B1 (en) 1998-04-23 2003-02-11 Abbott Laboratories Five-membered carbocyclic and heterocyclic inhibitors of neuraminidases
US6472389B1 (en) 1998-05-21 2002-10-29 Shionogi & Co., Ltd. Pyrrolo[1,2-b] pyridazine derivatives having sPLA2 inhibitory effect
US6268372B1 (en) 1998-09-11 2001-07-31 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,9-disubstituted purin-6-ones
WO2001010846A2 (en) 1999-08-05 2001-02-15 Igt Pharma Inc. 1,4-diazepine derivatives for the treatment of diseases related to the central nervous system
US6787545B1 (en) 1999-08-23 2004-09-07 Shiongi & Co., Ltd. Pyrrolotriazine derivatives having spla2-inhibitory activities
US6831069B2 (en) * 1999-08-27 2004-12-14 Ribapharm Inc. Pyrrolo[2,3-d]pyrimidine nucleoside analogs
BR0013642A (en) 1999-08-27 2002-05-07 Icn Pharmaceuticals Pyrrole [2,3-d] pyrimidine nucleoside analogs
UA72612C2 (en) 2000-07-06 2005-03-15 Pyrido[2.3-d]pyrimidine and pyrimido[4.5-d]pyrimidine nucleoside analogues, prodrugs and method for inhibiting growth of neoplastic cells
US20030175950A1 (en) 2001-05-29 2003-09-18 Mcswiggen James A. RNA interference mediated inhibition of HIV gene expression using short interfering RNA
DE10142100A1 (en) 2001-08-30 2003-04-03 Epcos Ag Electrolytic solution for capacitors and an electrolytic capacitor with the electrolytic solution and its use
AU2002351077A1 (en) 2001-11-05 2003-05-19 Exiqon A/S Oligonucleotides modified with novel alpha-l-rna analogues
JP2005525358A (en) 2002-02-28 2005-08-25 ビオタ インコーポレーティッド Nucleotide mimetics and their prodrugs
JP4384918B2 (en) 2002-04-18 2009-12-16 シェーリング コーポレイション (1-4-piperidinyl) benzimidazole derivatives useful as histamine H3 antagonists
US7220735B2 (en) 2002-04-18 2007-05-22 Schering Corporation Benzimidazolone histamine H3 antagonists
EP1506172B1 (en) 2002-05-20 2011-03-30 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
AU2003259735A1 (en) 2002-08-08 2004-02-25 Sirna Therapeutics, Inc. Small-mer compositions and methods of use
TW200410968A (en) 2002-10-11 2004-07-01 Ligand Pharm Inc 5-cycloalkenyl 5H-chromeno[3,4-f]quinoline derivatives as selective progesterone receptor modulator compounds
US7834021B2 (en) 2002-11-27 2010-11-16 Incyte Corporation 3-aminopyrrolidine derivatives as modulators of chemokine receptors
WO2004081643A1 (en) 2002-12-20 2004-09-23 Kaiser Aerospace & Electronics Corp. Lenslet array with polarization conversion
ES2320994T3 (en) 2003-04-04 2009-06-01 Novartis Ag DERIVATIVES OF QUINOLINA-2-ONA FOR THE TREATMENT OF DISEASES OF RESPIRATORY ROADS.
JP4661029B2 (en) 2003-05-22 2011-03-30 東ソー株式会社 Optically active maleimide derivative, optically active polymaleimide derivative, production method thereof, separating agent comprising optically active polymaleimide derivative, and separation method of optically active compound using the same
WO2004106356A1 (en) 2003-05-27 2004-12-09 Syddansk Universitet Functionalized nucleotide derivatives
EP1660511B1 (en) 2003-08-27 2010-11-03 Biota Scientific Management Pty. Ltd. Novel tricyclic nucleosides or nucleotides as therapeutic agents
US20080234498A1 (en) 2003-10-08 2008-09-25 President And Fellow Of Harvard College Pyrovalerone Analogues and Therapeutic Uses Thereof
EP1679069A4 (en) 2003-10-21 2009-05-13 Dainippon Sumitomo Pharma Co Novel piperidine derivative
OA13338A (en) 2003-12-18 2007-04-13 Incyte Corp 3-cycloalkylaminopyrrolidine derivates as modulators of chemokine receptors.
WO2005063766A2 (en) 2003-12-23 2005-07-14 Novartis Ag Bicyclic heterocyclic p-38 kinase inhibitors
US20080096922A1 (en) 2004-04-06 2008-04-24 Dainippon Sumitomo Pharma Co., Ltd. Novel Sulfonamide derivative
AR048523A1 (en) 2004-04-07 2006-05-03 Kalypsys Inc COMPOUNDS WITH ARIL SULFONAMIDE AND SULFONYL STRUCTURE AS PPAR MODULATORS AND METHODS TO TREAT METABOLIC DISORDERS
JP2008504280A (en) 2004-06-24 2008-02-14 インサイト・コーポレイション 2-methylpropanamide and its pharmaceutical use
EP1616874A1 (en) 2004-07-14 2006-01-18 Universiteit Gent Mono- and bicyclic compounds with therapeutic activity and pharmaceutical compositions including them
JP2006124326A (en) 2004-10-28 2006-05-18 Sumitomo Chemical Co Ltd Method for producing clopidogrel
WO2006081264A1 (en) 2005-01-25 2006-08-03 Glaxo Group Limited Antibacterial agents
PT1848718E (en) 2005-02-04 2012-10-11 Millennium Pharm Inc Inhibitors of e1 activating enzymes
JP2006241090A (en) 2005-03-04 2006-09-14 Tosoh Corp Method for separating optically active carboxylic acids
WO2006094347A1 (en) 2005-03-08 2006-09-14 Biota Scientific Management Pty Ltd. Bicyclic nucleosides and nucleotides as therapeutic agents
EP1866298A2 (en) 2005-03-31 2007-12-19 Takeda San Diego, Inc. Hydroxysteroid dehydrogenase inhibitors
CN101203510A (en) 2005-06-20 2008-06-18 先灵公司 Carbon-linked substituted piperidines and derivatives thereof used as histamine H3 antagonists
ATE450526T1 (en) 2005-06-20 2009-12-15 Schering Corp PIPERIDINE DERIVATIVES SUITABLE AS ANTAGONISTS OF HISTAMINE H3
DE102005059892A1 (en) 2005-12-15 2007-06-28 Bayer Cropscience Ag New spirocyclic tetramic acid derivatives useful as pesticides, herbicides and/or fungicides
DE102005059891A1 (en) 2005-12-15 2007-06-28 Bayer Cropscience Ag New spiro-cyclopentyl-pyrrole or -furan derivatives, useful as pesticides, herbicides and fungicides, also new intermediates
BRPI0620058A2 (en) 2005-12-20 2011-11-01 Novartis Ag a pharmaceutical combination comprising smac protein binding inhibitor compounds and apoptosis inhibitor proteins, and a taxane, as well as use thereof
AU2006331994A1 (en) 2005-12-21 2007-07-05 Schering Corporation Combination of an H3 antagonist/inverse agonist and an appetite suppressant
US7612101B2 (en) 2006-04-24 2009-11-03 Allergan, Inc. Abnormal cannabidiols as agents for lowering intraocular pressure
AU2007244978B2 (en) 2006-04-24 2013-05-30 Allergan, Inc. Abnormal Cannabidiols as agents for lowering intraocular pressure
NZ574513A (en) 2006-08-08 2012-02-24 Millennium Pharm Inc Heteroaryl compounds useful as inhibitors of e1 activating enzymes
JP5394249B2 (en) 2006-11-28 2014-01-22 ノバルティス アーゲー Combination of IAP inhibitor and FLT3 inhibitor
DE102006056740A1 (en) 2006-12-01 2008-06-05 Bayer Healthcare Ag Cyclic substituted 3,5-dicyano-2-thiopyridines and their use
CN101195586A (en) 2006-12-05 2008-06-11 中国科学院上海药物研究所 Compound with substituted cyclopentane structure, production method and medicine use thereof
EP2124913A1 (en) 2006-12-22 2009-12-02 Novartis AG 1-aminomethyl- l- phenyl- cyclohexane derivatives as ddp-iv inhibitors
WO2008138843A1 (en) 2007-05-10 2008-11-20 Galapagos N.V. Imidazopyridines and triazolopyrimidines useful for the treatment of joint degenerative & inflammatory diseases
EP2540726B1 (en) 2007-08-02 2019-10-09 Millennium Pharmaceuticals, Inc. Intermediates for the synthesis of E1 activity activating enzyme inhibitors
US8598165B2 (en) 2007-11-26 2013-12-03 University Of Kansas Morpholines as selective inhibitors of cytochrome P450 2A13
WO2009124103A2 (en) 2008-04-02 2009-10-08 Schering Corporation Combination therapies comprising par1 antagonists with par4 antagonists
CA2721586A1 (en) 2008-04-15 2009-10-22 Mallinckrodt Inc. Compositions containing antiviral compounds and methods of using the same
CA2722704A1 (en) 2008-04-28 2009-11-05 Zalicus Pharmaceuticals Ltd. Cyclylamine derivatives as calcium channel blockers
WO2010030858A1 (en) 2008-09-15 2010-03-18 Enanta Pharmaceuticals, Inc. 4'-allene-substituted nucleoside derivatives
WO2010051085A1 (en) 2008-10-30 2010-05-06 Oncotherapy Science, Inc. 7-hydroxy-benzoimidazole-4-yl-methanone derivatives and pbk inhibitors containing the same
US8722082B2 (en) 2008-11-10 2014-05-13 Tekmira Pharmaceuticals Corporation Lipids and compositions for the delivery of therapeutics
BRPI0920959A2 (en) 2008-11-20 2017-07-11 Oncotherapy Science Inc GLYCOGEN SYNTASE KINASE-3 BETA INHIBITORS CONTAINING 7-HYDROXY-BENZOIMIDAZOL-4-YL-METANONE DERIVATIVES
CA2751458C (en) 2009-02-06 2018-06-05 Rfs Pharma, Llc Purine nucleoside monophosphate prodrugs for treatment of cancer and viral infections
AP2011005929A0 (en) 2009-03-20 2011-10-31 Alios Biopharma Inc Substituted nucleoside and nucleotide analogs.
EP2264169A1 (en) 2009-06-15 2010-12-22 Qiagen GmbH Modified siNA
WO2011005595A2 (en) 2009-06-24 2011-01-13 Alios Biopharma, Inc. 2-5a analogs and their methods of use
WO2011005860A2 (en) 2009-07-07 2011-01-13 Alnylam Pharmaceuticals, Inc. 5' phosphate mimics
KR101049260B1 (en) 2009-07-23 2011-07-13 주식회사 엘지화학 New post metallocene transition metal compound
UA107360C2 (en) 2009-08-05 2014-12-25 Biogen Idec Inc Bicyclic aryl sphingosine 1-phosphate analogs
AR077859A1 (en) 2009-08-12 2011-09-28 Boehringer Ingelheim Int COMPOUNDS FOR THE TREATMENT OF CNS DISORDERS
CN102498111A (en) 2009-09-10 2012-06-13 诺瓦提斯公司 Sulfonamides as inhibitors of Bcl-2 family proteins for the treatment of cancer
WO2011057204A2 (en) 2009-11-06 2011-05-12 The Johns Hopkins University Lrrk2-mediated neuronal toxicity
WO2011061590A1 (en) 2009-11-17 2011-05-26 Hetero Research Foundation Novel carboxamide derivatives as hiv inhibitors
WO2011066482A2 (en) 2009-11-25 2011-06-03 Cytokine Pharmasciences, Inc. Chiral synthesis of isoxazolines, isoxazoline compounds, and uses thereof
EP3255038A1 (en) 2009-12-18 2017-12-13 Ogeda Sa Pyrrolidine carboxylic acid derivatives, pharmaceutical composition and methods for use in treating metabolic disorders as agonists of g-protein coupled receptor 43 (gpr43)
US9433621B2 (en) 2010-02-18 2016-09-06 Merck Sharp & Dohme Corp. Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
US9725479B2 (en) 2010-04-22 2017-08-08 Ionis Pharmaceuticals, Inc. 5′-end derivatives
US8735312B2 (en) 2010-04-23 2014-05-27 Lg Chem, Ltd. Catalyst composition and process for preparing olefin polymer using the same
JP2013147430A (en) 2010-04-28 2013-08-01 Astellas Pharma Inc Prophylactic or therapeutic agent for night urination
KR20110123657A (en) 2010-05-07 2011-11-15 에스케이케미칼주식회사 Picolinamide and pyrimidine-4-carboxamide compounds, process for preparing and pharmaceutical composition comprising the same
AU2011261499B2 (en) 2010-06-01 2015-07-16 Biotheryx, Inc. Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating proliferative diseases
WO2012025857A1 (en) 2010-08-23 2012-03-01 Hetero Research Foundation Cycloalkyl methoxybenzyl phenyl pyran derivatives as sodium dependent glucose co transporter (sglt2) inhibitors
WO2012028331A1 (en) 2010-09-03 2012-03-08 Grünenthal GmbH Substituted tetrahydropyrrolopyrazine derivatives
US20120070411A1 (en) 2010-09-22 2012-03-22 Alios Biopharma, Inc. Substituted nucleotide analogs
WO2012040127A1 (en) 2010-09-22 2012-03-29 Alios Biopharma, Inc. Substituted nucleotide analogs
ES2624845T3 (en) 2010-09-29 2017-07-17 Intervet International B.V. N-heteroaryl compounds with cyclic bridge unit for the treatment of parasitic diseases
MX2013006251A (en) 2010-12-03 2013-10-01 Epizyme Inc Substituted purine and 7 - deazapurine compounds as modulators of epigenetic enzymes.
WO2012114223A1 (en) 2011-02-25 2012-08-30 Pfizer Limited A method of treating liver fibrosis
EP2508511A1 (en) 2011-04-07 2012-10-10 Laboratoire Biodim Inhibitors of viral replication, their process of preparation and their therapeutical uses
EP2734525A4 (en) 2011-07-19 2015-03-04 Univ Idaho Embodiments of a probe and method for targeting nucleic acids
CN102924457A (en) 2011-08-12 2013-02-13 上海恒瑞医药有限公司 Triazolopyrimidine derivatives, preparation method and uses thereof
CA2847540C (en) 2011-09-22 2016-05-17 Pfizer Inc. Pyrrolopyrimidine and purine derivatives
CN103102345B (en) 2011-11-14 2015-06-03 广东东阳光药业有限公司 Aminoquinazoline derivative, salts thereof and application method
WO2013096939A1 (en) 2011-12-23 2013-06-27 Sri International Selective binding compounds
WO2013120040A1 (en) 2012-02-10 2013-08-15 Children's Medical Center Corporation Targeted pathway inhibition to improve muscle structure, function and activity in muscular dystrophy
WO2013151975A1 (en) 2012-04-02 2013-10-10 Northeastern University Compositions and methods for the inhibition of methyltransferases
WO2013188881A1 (en) 2012-06-15 2013-12-19 President And Fellows Of Harvard College Compounds, compositions and methods for treating or preventing neurodegenerative disorders
TW201408652A (en) 2012-07-11 2014-03-01 Hoffmann La Roche Aryl sultam derivatives as RORc modulators
EP2882750A4 (en) 2012-08-10 2016-08-17 Epizyme Inc Inhibitors of protein methyltransferase dot1l and methods of use thereof
MX2015002511A (en) 2012-08-24 2016-03-08 Sunshine Lake Pharma Co Ltd Dihydropyrimidine compounds and their application in pharmaceuticals.
CN104884462A (en) 2012-10-29 2015-09-02 共晶制药股份有限公司 Pyrimidine nucleotides and their monophosphate prodrugs for treatment of viral infections and cancer
CA2893638A1 (en) 2012-12-10 2014-06-19 F. Hoffmann-La Roche Ag Benzyl sulfonamide derivatives as rorc modulators
AU2014236348B2 (en) 2013-03-14 2018-05-10 Epizyme, Inc. Combination therapy for treating cancer
US9783488B2 (en) 2013-03-14 2017-10-10 Chdi Foundation, Inc. Histone deacetylase inhibitors and compositions and methods of use thereof
PT2989098T (en) 2013-03-15 2017-08-16 Cayman Chemical Co Inc Lactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated diseases and conditions
TW201524952A (en) 2013-03-15 2015-07-01 Araxes Pharma Llc Covalent inhibitors of KRAS G12C
UY35464A (en) 2013-03-15 2014-10-31 Araxes Pharma Llc KRAS G12C COVALENT INHIBITORS.
WO2015077360A2 (en) 2013-11-20 2015-05-28 Idenix Pharmaceuticals, Inc. Cyclopentane and cyclopentene nucleoside analogs for the treatment of hcv
TWI608080B (en) 2014-01-29 2017-12-11 達興材料股份有限公司 Liquid crystal compound, liquid crystal composition and liquid crystal display device having thereof
MX2016010105A (en) * 2014-02-06 2016-11-15 Riboscience Llc 4'-difluoromethyl substituted nucleoside derivatives as inhibitors of influenza rna replication.
EP3145912A1 (en) 2014-05-23 2017-03-29 F. Hoffmann-La Roche AG Benzene sulfonamide derivatives and their use as rorc modulators
CN104059674B (en) 2014-06-06 2016-01-20 北京八亿时空液晶科技股份有限公司 A kind of liquid crystalline cpd and application thereof containing difluoro-methoxy bridged bond
CN104087312B (en) 2014-06-17 2016-07-06 北京八亿时空液晶科技股份有限公司 A kind of liquid-crystal composition and application thereof
EP3160475B1 (en) * 2014-06-24 2024-01-03 Janssen Pharmaceuticals, Inc. Substituted nucleosides and nucleotides to treat filoviridae infections
AR101214A1 (en) 2014-07-22 2016-11-30 Bayer Cropscience Ag CIANO-CICLOALQUILPENTA-2,4-DIENOS, CIANO-CICLOALQUILPENT-2-EN-4-INAS, CIANO-HETEROCICLILPENTA-2,4-DIENOS AND CYANO-HETEROCICLILPENT-2-EN-4-INAS REPLACED AS ACTIVE PRINCIPLES PLANTS ABIOTIC
RU2017105133A (en) 2014-07-31 2018-08-28 Мерк Патент Гмбх INDOLYSINE DERIVATIVES THAT USE FOR NEURODEGENERATIVE DISEASES
JP6585158B2 (en) 2014-08-12 2019-10-02 ファイザー・インク Pyrrolo [2,3-d] pyrimidine derivatives useful for the inhibition of Janus kinase
JP2017532312A (en) 2014-09-17 2017-11-02 エピザイム，インコーポレイティド Combination therapy to treat cancer
JO3556B1 (en) 2014-09-18 2020-07-05 Araxes Pharma Llc Combination therapies for treatment of cancer
ES2826443T3 (en) 2014-09-25 2021-05-18 Araxes Pharma Llc KRAS G12C Mutant Protein Inhibitors
WO2016049565A1 (en) 2014-09-25 2016-03-31 Araxes Pharma Llc Compositions and methods for inhibition of ras
JP6671355B2 (en) * 2014-09-26 2020-03-25 リボサイエンス・エルエルシー 4'-Vinyl-substituted nucleoside derivatives as inhibitors of respiratory syncytial virus RNA replication
WO2016066582A1 (en) 2014-10-28 2016-05-06 Bci Pharma Nucleoside kinase inhibitors
US10421696B2 (en) 2014-12-18 2019-09-24 California Institute Of Technology Enantioselective synthesis of α-quaternary mannich adducts by palladium-catalyzed allylic alkylation
WO2016115416A1 (en) 2015-01-15 2016-07-21 The Trustees Of Columbia University In The City Of New York Methods of producing metal suflides, metal selenides, and metal sulfides/selenides having controlled architectures using kinetic control
WO2016145142A1 (en) 2015-03-10 2016-09-15 Emory University Nucleotide and nucleoside therapeutics compositions and uses related thereto
FR3034767A1 (en) 2015-04-07 2016-10-14 Centre Nat Rech Scient REDUCTION OF THE CARBONYL FUNCTIONS OF CARBOHYDRATES AND AQUEOUS CARBOHYDRATE DERIVATIVES BY SODIUM DITHIONITE
CA2995093A1 (en) 2015-08-10 2017-02-16 Alzheon, Inc. Compositions and methods for treating and preventing neurodegenerative disorders
TWI730980B (en) 2015-08-26 2021-06-21 比利時商健生藥品公司 Novel 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as prmt5 inhibitors
US9926277B2 (en) 2015-10-02 2018-03-27 Biotheryx, Inc. Pyridone compounds, pharmaceutical compositions thereof, and their therapeutic use for treating proliferative diseases
US11433047B2 (en) 2015-10-09 2022-09-06 Neurotheryx Canada Ltd. Pharmaceutical compositions comprising one or more pyrone compounds, and their use for treating inflammatory and neurodegenerative diseases
WO2017066791A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Sugar substituted mrna cap analogs
SI3362461T1 (en) 2015-10-16 2022-05-31 Modernatx, Inc. Mrna cap analogs with modified phosphate linkage
WO2017066789A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Mrna cap analogs with modified sugar
AU2016340183A1 (en) 2015-10-16 2018-04-19 Modernatx, Inc. mRNA cap analogs and methods of mRNA capping
WO2017066782A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Hydrophobic mrna cap analogs
US11866754B2 (en) 2015-10-16 2024-01-09 Modernatx, Inc. Trinucleotide mRNA cap analogs
WO2017099969A1 (en) 2015-12-10 2017-06-15 Merck Sharp & Dohme Corp. Tetrahydroquinoxaline m1 receptor positive allosteric modulators
WO2017117443A1 (en) 2015-12-31 2017-07-06 Braskem America, Inc. Non-phthalate catalyst system and its use in the polymerization of olefins
AU2017230658B2 (en) 2016-03-10 2021-03-04 Janssen Pharmaceutica Nv Substituted nucleoside analogues for use as PRMT5 inhibitors
CA2969295A1 (en) 2016-06-06 2017-12-06 Pfizer Inc. Substituted carbonucleoside derivatives, and use thereof as a prmt5 inhibitor
CN109071392B (en) 2016-06-08 2020-10-02 四川海思科制药有限公司 Benzene ring derivative, preparation method and medical application thereof
WO2018022761A1 (en) 2016-07-27 2018-02-01 Blueprint Medicines Corporation Substituted cyclopentane-amides for treating disorders related to ret
CN107674013B (en) 2016-08-02 2022-05-24 上海迪诺医药科技有限公司 Polycyclic compound, preparation method, pharmaceutical composition and application thereof
CN107674029A (en) 2016-08-02 2018-02-09 上海迪诺医药科技有限公司 Polycyclic compound, its pharmaceutical composition and application
CN107793409B (en) 2016-09-05 2022-09-27 广东东阳光药业有限公司 Dihydropyrimidine compound and application thereof in medicine
WO2018065365A1 (en) * 2016-10-03 2018-04-12 Janssen Pharmaceutica Nv Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors
WO2018065354A1 (en) 2016-10-03 2018-04-12 Umicore Ag & Co. Kg Catalyst article and method for the abatement of ammonia and nitrogen oxides
JP2018070512A (en) 2016-10-31 2018-05-10 住友化学株式会社 Harmful arthropod control composition
WO2018081863A1 (en) 2016-11-04 2018-05-11 University Of Wollongong 6-SUBSTITUTED DERIVATIVES OF HEXAMETHYLENE AMILORIDE AS INHIBITORS OF uPA AND USES THEREOF
WO2018085818A1 (en) * 2016-11-07 2018-05-11 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
CN108276463A (en) 2017-01-06 2018-07-13 米文君 A new class of compound and application thereof
WO2018152548A1 (en) 2017-02-20 2018-08-23 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
WO2018152501A1 (en) 2017-02-20 2018-08-23 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
MY195860A (en) 2017-02-27 2023-02-24 Janssen Pharmaceutica Nv Use of Biomarkers in Identifying Cancer Patients That will be Responsive to Treatment with a Prmt5 Inhibitor
WO2018160824A1 (en) 2017-03-01 2018-09-07 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
JP7178357B2 (en) 2017-03-07 2022-11-25 エフ．ホフマン－ラ ロシュ アーゲー Oxadiazole transient receptor potential channel inhibitor
WO2018213258A1 (en) 2017-05-15 2018-11-22 Millennium Pharmaceuticals, Inc. Treatment of merlin-deficient tumors using nae inhibitors
JP7088965B2 (en) 2017-06-09 2022-06-21 ブリストル－マイヤーズ スクイブ カンパニー Aryl Heterocyclic Piperidinone Formyl Peptide 2 Receptor and Formyl Peptide 1 Receptor Agonist
KR20200096265A (en) 2017-12-05 2020-08-11 앤젝스 파마수티컬, 인크. Heterocyclic compounds as PRMT5 inhibitors
US11459330B2 (en) * 2017-12-13 2022-10-04 Lupin Limited Substituted bicyclic heterocyclic compounds as PRMT5 inhibitors
KR20190076339A (en) 2017-12-22 2019-07-02 한미약품 주식회사 Novel 2,6-naphthyridine 2-oxide derivatives and use thereof
EP3765006A4 (en) 2018-03-13 2022-02-23 Merck Sharp & Dohme Corp. Arginase inhibitors and methods of use
CN110386954B (en) 2018-04-16 2020-08-21 中国科学院化学研究所 Asymmetric fused ring pyridine imino containing complex and preparation method and application thereof
CN112423764A (en) 2018-04-30 2021-02-26 欧瑞克制药公司 CD73 inhibitor
WO2020033284A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
US20210309687A1 (en) 2018-08-07 2021-10-07 Merck Sharp & Dohme Corp. Prmt5 inhibitors
KR20210046009A (en) 2018-08-07 2021-04-27 머크 샤프 앤드 돔 코포레이션 PRMT5 inhibitor
US20210277009A1 (en) 2018-08-07 2021-09-09 Merck Sharp & Dohme Corp. Prmt5 inhibitors
CN113473985A (en) 2018-09-18 2021-10-01 百时美施贵宝公司 Cyclopentanoic acid as LPA antagonist
BR112021019465A8 (en) * 2019-04-02 2022-06-07 Aligos Therapeutics Inc Compounds that target prmt5
CN110423265A (en) 2019-04-03 2019-11-08 中国药科大学 A kind of preparation method and purposes of cyclic peptide TRF2 inhibitor

Also Published As

Publication number Publication date
MA55556A (en) 2022-02-09
CN114072407A (en) 2022-02-18
CA3134613A1 (en) 2020-10-08
BR112021019465A8 (en) 2022-06-07
EP3947388A4 (en) 2022-12-21
KR20210145787A (en) 2021-12-02
US20220048922A1 (en) 2022-02-17
US20200317686A1 (en) 2020-10-08
US11198699B2 (en) 2021-12-14
JP2022522534A (en) 2022-04-19
BR112021019465A2 (en) 2022-02-15
TW202102509A (en) 2021-01-16
IL286849A (en) 2021-10-31
AU2020256166A1 (en) 2021-10-14
WO2020205867A1 (en) 2020-10-08
MX2021011606A (en) 2021-12-10
EP3947388A1 (en) 2022-02-09

Similar Documents

Publication Publication Date Title
IL286849A (en) Compounds targeting prmt5
IL290341A (en) Mta-cooperative prmt5 inhibitors
EP3833355A4 (en) Prmt5 inhibitors
EP3833669A4 (en) Prmt5 inhibitors
GB201905721D0 (en) Compounds
EP3833668A4 (en) Prmt5 inhibitors
IL288734A (en) Substituted pyridazinones as herbicides
IL288733A (en) Substituted pyridazinones as herbicides
EP4077282A4 (en) Prmt5 inhibitors
ZA202109573B (en) Prmt5 inhibitors
GB201910305D0 (en) Compounds
EP4076459A4 (en) Prmt5 inhibitors
EP3833667A4 (en) Prmt5 inhibitors
GB201908536D0 (en) Compounds
GB201908171D0 (en) Compounds
EP4076452A4 (en) Prmt5 inhibitors
GB201910304D0 (en) Compounds
GB201908095D0 (en) Carboxy-MIDA-boronate compounds
IL282030A (en) Antibodies targeting epn1
EP4076460A4 (en) Prmt5 inhibitors
GB201913541D0 (en) Compounds
GB201912850D0 (en) Compounds
GB201911848D0 (en) Compounds
GB201910885D0 (en) Compounds
GB201910608D0 (en) Compounds